EPRAZINONE HYDROCHLORIDE

Details

Stereochemistry	MIXED
Molecular Formula	C24H32N2O2.2ClH
Molecular Weight	453.445
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.Cl.CCOC(CN1CCN(CC(C)C(=O)C2=CC=CC=C2)CC1)C3=CC=CC=C3

InChI

InChIKey=BPMQVOKMMQFZGV-UHFFFAOYSA-N

InChI=1S/C24H32N2O2.2ClH/c1-3-28-23(21-10-6-4-7-11-21)19-26-16-14-25(15-17-26)18-20(2)24(27)22-12-8-5-9-13-22;;/h4-13,20,23H,3,14-19H2,1-2H3;2*1H

HIDE SMILES / InChI

Description
Sources: https://chugai-pharm.jp/hc/ss/pr/drug/res_fil0020/shiori/PDF/en/res_t_s_en.pdf
Curator's Comment: description was created based on several sources, including: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=421 | http://en.pharmacodia.com/web/drug/1_11802.html

Eprazinone has been variously described as having mucolytic or expectorant properties as well as a direct relaxant action on bronchial smooth muscle and it suppress the excitation of cough center to stop coughing. It is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia The most commonly reported adverse reactions include loss of appetite, nausea/vomiting, stomach discomfort, diarrhea (including loose stool) and symptom of irritation.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Neurokinin 1 receptor 35 Target ID: CHEMBL249 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24849814	Antagonist 2778

Conditions

Condition	Modality	Highest Phase	Product
Upper respiratory infection 2 Sources: https://web.archive.org/web/20160304114246/http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=421	Palliative	Approved 8429	Eftapan Approved Use It is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia
Bronchitis 51 Sources: https://web.archive.org/web/20160304114246/http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=421	Palliative	Approved 8429	Eftapan Approved Use It is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia
Common cold 58 Sources: https://web.archive.org/web/20160304114246/http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=421	Palliative	Approved 8429	Eftapan Approved Use It is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia.
Pneumonia 90 Sources: https://web.archive.org/web/20160304114246/http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=421	Palliative	Approved 8429	Eftapan Approved Use It is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia.

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

take 60-90mg of the active ingredient in 3 divided doses a day

Route of Administration: Other

In Vitro Use Guide

Eprazinone displayed a rather weak inhibition of [125I]BH-SPbinding to NK1R, at a concentration of 25 uM, and an antagonistic effect of about 30%, NK1R blockade could contribute to its mucolytic activity or could even be a hint to a still unrevealed mode of action.

Name

Type

Language

EPRAZINONE HYDROCHLORIDE

Common Name

English

NSC-317935

Code

English

EPRAZINONE HCL

Common Name

English

EPRAZINONE HYDROCHLORIDE [JAN]

Common Name

English

EPRAZINONE HYDROCHLORIDE [MART.]

Common Name

English

Eprazinone hydrochloride [WHO-DD]

Common Name

English

3-(4-(.BETA.-ETHOXYPHENETHYL)PIPERAZIN-1-YL)-2-METHYLPROPIOPHENONE DIHYDROCHLORIDE

Systematic Name

English

EPRAZINONE DIHYDROCHLORIDE [MI]

Common Name

English

Code System Code Type Description

PUBCHEM

73356